Sources Database

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Fatigue

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Fatigue occurred in 12 participants (34.3%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Fatigue

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Fatigue occurred in 10 participants (28.6%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Headache

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Headache occurred in 14 participants (40.0%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Headache

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Headache occurred in 10 participants (28.6%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Cholelithiasis

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Cholelithiasis occurred in 2 participants (5.7%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Cholelithiasis

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Cholelithiasis occurred in 0 participants (0.0%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Dizziness

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Dizziness occurred in 12 participants (34.3%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Dizziness

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Dizziness occurred in 5 participants (14.3%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Abdominal pain

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Abdominal pain occurred in 8 participants (22.9%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Abdominal pain

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Abdominal pain occurred in 5 participants (14.3%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Constipation

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Constipation occurred in 13 participants (37.1%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Constipation

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Constipation occurred in 8 participants (22.9%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Vomiting

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Vomiting occurred in 10 participants (28.6%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Vomiting

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Vomiting occurred in 6 participants (17.1%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Decreased appetite

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Decreased appetite occurred in 15 participants (42.9%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Decreased appetite

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Decreased appetite occurred in 4 participants (11.4%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Nausea

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Nausea occurred in 24 participants (68.6%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Nausea

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Nausea occurred in 8 participants (22.9%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Diarrhoea

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Semaglutide 2.4mg" arm (n=35 at risk), Diarrhoea occurred in 21 participants (60.0%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

ClinicalTrials.gov results — Semaglutide 2.4 mg in Patients With Poor Weight-loss — Diarrhoea

Posted trial results for Semaglutide 2.4 mg in Patients With Poor Weight-loss (NCT05073835, PHASE3). In the "Placebo" arm (n=35 at risk), Diarrhoea occurred in 14 participants (40.0%). Conditions: Obesity, Diabetes, Metabolic Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: 74 weeks (68 weeks of treatment and 6 week wash out period)

PubMed — GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.

J Intern Med. 2026 Oct 9. doi: 10.1111/joim.70170. Online ahead of print. GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications. Ueda P(1)(2). Author information: (1)Centre for Pharmacoepidemiology, Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. (2)Centre for Diabetes, Academic Specialist Centre, Region Stockholm, Stockholm, Sweden. Glucagon-like peptide-1 (GLP-1) receptor agonists p

PubMed — GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.

J Intern Med. 2026 Oct 9. doi: 10.1111/joim.70170. Online ahead of print. GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications. Ueda P(1)(2). Author information: (1)Centre for Pharmacoepidemiology, Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. (2)Centre for Diabetes, Academic Specialist Centre, Region Stockholm, Stockholm, Sweden. Glucagon-like peptide-1 (GLP-1) receptor agonists p

PubMed — GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.

Reprod Biomed Online. 2019 Aug;39(2):332-342. doi: 10.1016/j.rbmo.2019.04.017. Epub 2019 Apr 25. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Han Y(1), Li Y(1), He B(2). Author information: (1)Department of Endocrinology, Shengjing Hospital, China Medical University, Shenyang, China. (2)Department of Endocrinology, Shengjing Hospital, China Medical University, Shenyang, China. Electronic address: hb3h@hotmail.com. This meta-analysis aimed to ev

PubMed — GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.

Reprod Biomed Online. 2019 Aug;39(2):332-342. doi: 10.1016/j.rbmo.2019.04.017. Epub 2019 Apr 25. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Han Y(1), Li Y(1), He B(2). Author information: (1)Department of Endocrinology, Shengjing Hospital, China Medical University, Shenyang, China. (2)Department of Endocrinology, Shengjing Hospital, China Medical University, Shenyang, China. Electronic address: hb3h@hotmail.com. This meta-analysis aimed to ev

Google News (Quora Q&A search) — Is nausea and vomiting common in people who have diabetes? - Quora

Quora Q&A: Is nausea and vomiting common in people who have diabetes? - Quora Published: Wed, 03 May 2023 07:00:00 GMT Is nausea and vomiting common in people who have diabetes?  Quora

Google News (Quora Q&A search) — Is nausea and vomiting common in people who have diabetes? - Quora

Quora Q&A: Is nausea and vomiting common in people who have diabetes? - Quora Published: Wed, 03 May 2023 07:00:00 GMT Is nausea and vomiting common in people who have diabetes?  Quora

Trial Site News (EMA-safety search) — New Tirzepatide Safety Review Finds Pancreatitis and Gallbladder Complications—B

New Tirzepatide Safety Review Finds Pancreatitis and Gallbladder Complications—But How Great Is the Risk? - Trial Site News Source: Trial Site News Published: Fri, 23 Oct 2026 15:34:15 GMT New Tirzepatide Safety Review Finds Pancreatitis and Gallbladder Complications—But How Great Is the Risk?  Trial Site News

Trial Site News (EMA-safety search) — New Tirzepatide Safety Review Finds Pancreatitis and Gallbladder Complications—B

New Tirzepatide Safety Review Finds Pancreatitis and Gallbladder Complications—But How Great Is the Risk? - Trial Site News Source: Trial Site News Published: Fri, 23 Oct 2026 15:34:15 GMT New Tirzepatide Safety Review Finds Pancreatitis and Gallbladder Complications—But How Great Is the Risk?  Trial Site News

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Dizziness

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Dizziness occurred in 4 participants (7.4%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving act

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Dizziness

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Dizziness occurred in 6 participants (11.1%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receivin

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Abdominal Pain

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Abdominal Pain occurred in 3 participants (5.6%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receivin

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Abdominal Pain

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Abdominal Pain occurred in 5 participants (9.3%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was rece

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Vomiting

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Vomiting occurred in 3 participants (5.6%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving acti

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Vomiting

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Vomiting occurred in 9 participants (16.7%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Fatigue

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Fatigue occurred in 8 participants (14.8%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving acti

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Fatigue

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Fatigue occurred in 16 participants (29.6%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Diarrhea

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Diarrhea occurred in 17 participants (31.5%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving ac

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Diarrhea

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Diarrhea occurred in 7 participants (13.0%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Nausea

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Nausea occurred in 11 participants (20.4%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving acti

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Nausea

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Nausea occurred in 21 participants (38.9%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was receiving

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Injection Site Reaction

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Placebo Arm" arm (n=54 at risk), Injection Site Reaction occurred in 2 participants (3.7%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant was

ClinicalTrials.gov results — Effects of Semaglutide in HIV-Associated Lipohypertrophy — Injection Site Reaction

Posted trial results for Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197, PHASE2). In the "Participants With HIV and Lipohypertrophy: Semaglutide Arm" arm (n=54 at risk), Injection Site Reaction occurred in 4 participants (7.4%). Conditions: HIV/AIDS, Lipohypertrophy, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse event data were collected for participants during the time when each participant

Psychology Today — A Hidden Danger of Using Weight-Loss Medication - Psychology Today

A Hidden Danger of Using Weight-Loss Medication - Psychology Today Source: Psychology Today Published: Thu, 06 Aug 2026 07:00:00 GMT Updated August 6, 2026 | Reviewed by Kaja Perina Co-written with Jenna Moore, RD, CSSD As a psychiatrist, I've seen the mental health benefits that go along with successful weight loss—improved mood, enhanced self-esteem, and reduced anxiety. And as a registered di

Psychology Today — A Hidden Danger of Using Weight-Loss Medication - Psychology Today

A Hidden Danger of Using Weight-Loss Medication - Psychology Today Source: Psychology Today Published: Thu, 06 Aug 2026 07:00:00 GMT Updated August 6, 2026 | Reviewed by Kaja Perina Co-written with Jenna Moore, RD, CSSD As a psychiatrist, I've seen the mental health benefits that go along with successful weight loss—improved mood, enhanced self-esteem, and reduced anxiety. And as a registered di

Psychology Today — A Hidden Danger of Using Weight-Loss Medication - Psychology Today

A Hidden Danger of Using Weight-Loss Medication - Psychology Today Source: Psychology Today Published: Thu, 06 Aug 2026 07:00:00 GMT Updated August 6, 2026 | Reviewed by Kaja Perina Co-written with Jenna Moore, RD, CSSD As a psychiatrist, I've seen the mental health benefits that go along with successful weight loss—improved mood, enhanced self-esteem, and reduced anxiety. And as a registered di

Dove Medical Press (EMA-safety search) — Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity

Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review - Dove Medical Press Source: Dove Medical Press Published: Thu, 22 Oct 2026 12:48:48 GMT Open access to scientific and medical research Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 19 Authors Kutsyba T , Raj S , van der Berg M Received 8 July 2026 Accepted for publication 30 September 2026 Published 23 October 2026 Volume 2026:19

Dove Medical Press (EMA-safety search) — Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity

Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review - Dove Medical Press Source: Dove Medical Press Published: Thu, 22 Oct 2026 12:48:48 GMT Open access to scientific and medical research Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 19 Authors Kutsyba T , Raj S , van der Berg M Received 8 July 2026 Accepted for publication 30 September 2026 Published 23 October 2026 Volume 2026:19

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

GoodRx — 5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx

5 Foods That Can Help You Manage GLP-1 Side Effects - GoodRx Source: GoodRx Published: Thu, 08 Oct 2026 07:00:00 GMT GLP-1 agonist medications can cause many side effects. The most common are nausea, stomach upset, and bowel habit changes. Most GLP-1 side effects go away on their own as your body adjusts to the medication. Eating the right foods can help minimize these side effects. Foods that can help ease GLP-1 side effects include lean proteins, fruits, vegetables, and whole grains. Gluc

The Grocer — Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation

Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation - The Grocer Source: The Grocer Published: Wed, 09 Sep 2026 07:00:00 GMT By Elinor Zuke2026-09-09T10:39:00+01:00 The General Pharmaceutical Council (GPhC) has said it is “very concerned” after an investigation by The Grocer found online pharmacy MedExpress prescribed Mounjaro to a patient with a healthy BMI without independently verifying the false weight submitted during the consultation. Mounjaro is licensed fo

The Grocer — Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation

Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation - The Grocer Source: The Grocer Published: Wed, 09 Sep 2026 07:00:00 GMT By Elinor Zuke2026-09-09T10:39:00+01:00 The General Pharmaceutical Council (GPhC) has said it is “very concerned” after an investigation by The Grocer found online pharmacy MedExpress prescribed Mounjaro to a patient with a healthy BMI without independently verifying the false weight submitted during the consultation. Mounjaro is licensed fo

The Grocer — Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation

Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation - The Grocer Source: The Grocer Published: Wed, 09 Sep 2026 07:00:00 GMT By Elinor Zuke2026-09-09T10:39:00+01:00 The General Pharmaceutical Council (GPhC) has said it is “very concerned” after an investigation by The Grocer found online pharmacy MedExpress prescribed Mounjaro to a patient with a healthy BMI without independently verifying the false weight submitted during the consultation. Mounjaro is licensed fo

The Grocer — Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation

Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation - The Grocer Source: The Grocer Published: Wed, 09 Sep 2026 07:00:00 GMT By Elinor Zuke2026-09-09T10:39:00+01:00 The General Pharmaceutical Council (GPhC) has said it is “very concerned” after an investigation by The Grocer found online pharmacy MedExpress prescribed Mounjaro to a patient with a healthy BMI without independently verifying the false weight submitted during the consultation. Mounjaro is licensed fo

The Grocer — Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation

Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation - The Grocer Source: The Grocer Published: Wed, 09 Sep 2026 07:00:00 GMT By Elinor Zuke2026-09-09T10:39:00+01:00 The General Pharmaceutical Council (GPhC) has said it is “very concerned” after an investigation by The Grocer found online pharmacy MedExpress prescribed Mounjaro to a patient with a healthy BMI without independently verifying the false weight submitted during the consultation. Mounjaro is licensed fo

The Grocer — Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation

Regulator ‘very concerned’ by MedExpress weight-loss prescription investigation - The Grocer Source: The Grocer Published: Wed, 09 Sep 2026 07:00:00 GMT By Elinor Zuke2026-09-09T10:39:00+01:00 The General Pharmaceutical Council (GPhC) has said it is “very concerned” after an investigation by The Grocer found online pharmacy MedExpress prescribed Mounjaro to a patient with a healthy BMI without independently verifying the false weight submitted during the consultation. Mounjaro is licensed fo

Google News (X/Twitter search) — GLP-1 weight-loss drugs change how people eat, but nausea needs closer study htt

Tweet/X post: GLP-1 weight-loss drugs change how people eat, but nausea needs closer study https://t.co/tBcxliHIbq via @beverley_oh et al - X Published: Fri, 23 Oct 2026 07:35:49 GMT GLP-1 weight-loss drugs change how people eat, but nausea needs closer study https://t.co/tBcxliHIbq via @beverley_oh et al  X

India News — 'Easy to get influenced': What cheaper weight-loss drugs means for millions - AB

'Easy to get influenced': What cheaper weight-loss drugs means for millions - ABC News & Headlines – Australian Broadcasting Corporation Published: Sat, 09 May 2026 07:00:00 GMT By Claire Campbell Topic:Health Pankhuri Pareek is one of an increasing number of Indian women prescribed Mounjaro to lose weight. (Supplied: Pankhuri Pareek) Several pharmaceutical companies have begun selling cheaper, generic brands of semaglutide weight loss drugs in India after the patent expired in March. More

India News — 'Easy to get influenced': What cheaper weight-loss drugs means for millions - AB

'Easy to get influenced': What cheaper weight-loss drugs means for millions - ABC News & Headlines – Australian Broadcasting Corporation Published: Sat, 09 May 2026 07:00:00 GMT By Claire Campbell Topic:Health Pankhuri Pareek is one of an increasing number of Indian women prescribed Mounjaro to lose weight. (Supplied: Pankhuri Pareek) Several pharmaceutical companies have begun selling cheaper, generic brands of semaglutide weight loss drugs in India after the patent expired in March. More

India News — 'Easy to get influenced': What cheaper weight-loss drugs means for millions - AB

'Easy to get influenced': What cheaper weight-loss drugs means for millions - ABC News & Headlines – Australian Broadcasting Corporation Published: Sat, 09 May 2026 07:00:00 GMT By Claire Campbell Topic:Health Pankhuri Pareek is one of an increasing number of Indian women prescribed Mounjaro to lose weight. (Supplied: Pankhuri Pareek) Several pharmaceutical companies have begun selling cheaper, generic brands of semaglutide weight loss drugs in India after the patent expired in March. More

India News — 'Easy to get influenced': What cheaper weight-loss drugs means for millions - AB

'Easy to get influenced': What cheaper weight-loss drugs means for millions - ABC News & Headlines – Australian Broadcasting Corporation Published: Sat, 09 May 2026 07:00:00 GMT By Claire Campbell Topic:Health Pankhuri Pareek is one of an increasing number of Indian women prescribed Mounjaro to lose weight. (Supplied: Pankhuri Pareek) Several pharmaceutical companies have begun selling cheaper, generic brands of semaglutide weight loss drugs in India after the patent expired in March. More

India News — 'Easy to get influenced': What cheaper weight-loss drugs means for millions - AB

'Easy to get influenced': What cheaper weight-loss drugs means for millions - ABC News & Headlines – Australian Broadcasting Corporation Published: Sat, 09 May 2026 07:00:00 GMT By Claire Campbell Topic:Health Pankhuri Pareek is one of an increasing number of Indian women prescribed Mounjaro to lose weight. (Supplied: Pankhuri Pareek) Several pharmaceutical companies have begun selling cheaper, generic brands of semaglutide weight loss drugs in India after the patent expired in March. More

India News — 'Easy to get influenced': What cheaper weight-loss drugs means for millions - AB

'Easy to get influenced': What cheaper weight-loss drugs means for millions - ABC News & Headlines – Australian Broadcasting Corporation Published: Sat, 09 May 2026 07:00:00 GMT By Claire Campbell Topic:Health Pankhuri Pareek is one of an increasing number of Indian women prescribed Mounjaro to lose weight. (Supplied: Pankhuri Pareek) Several pharmaceutical companies have begun selling cheaper, generic brands of semaglutide weight loss drugs in India after the patent expired in March. More

Google News (X/Twitter search) — Less Ozempic, less nausea? Some GLP-1 users are experimenting with smaller doses

Tweet/X post: Less Ozempic, less nausea? Some GLP-1 users are experimenting with smaller doses of weight-loss medicines to reduce side effects and costs. But doctors warn self-directed dose may affect weight loss & blood sugar control. @RichhariyaSneha explains. htt - X Published: Wed, 21 Oct 2026 02:30:00 GMT Less Ozempic, less nausea? Some GLP-1 users are experimenting with smaller doses of weight-loss medicines to reduce side effects and costs. But doctors warn self-directed dose may affect

Medscape — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape

Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape Source: Medscape Published: Thu, 22 Oct 2026 09:02:22 GMT Recent headlines hail Eli Lilly’s triple agonist retatrutide as “the most powerful weight-loss drug ever tested,” a “new high-water mark,” and a drug that “reaches surgery-level weight loss.” The weight-loss outcomes reported by the company for the experimental drug — a GLP-1, GIP, and glucagon agonist — are impressive. Depending on the trial, participants on the highest

Medscape — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape

Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape Source: Medscape Published: Thu, 22 Oct 2026 09:02:22 GMT Recent headlines hail Eli Lilly’s triple agonist retatrutide as “the most powerful weight-loss drug ever tested,” a “new high-water mark,” and a drug that “reaches surgery-level weight loss.” The weight-loss outcomes reported by the company for the experimental drug — a GLP-1, GIP, and glucagon agonist — are impressive. Depending on the trial, participants on the highest

Medscape — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape

Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape Source: Medscape Published: Thu, 22 Oct 2026 09:02:22 GMT Recent headlines hail Eli Lilly’s triple agonist retatrutide as “the most powerful weight-loss drug ever tested,” a “new high-water mark,” and a drug that “reaches surgery-level weight loss.” The weight-loss outcomes reported by the company for the experimental drug — a GLP-1, GIP, and glucagon agonist — are impressive. Depending on the trial, participants on the highest

Medscape — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape

Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape Source: Medscape Published: Thu, 22 Oct 2026 09:02:22 GMT Recent headlines hail Eli Lilly’s triple agonist retatrutide as “the most powerful weight-loss drug ever tested,” a “new high-water mark,” and a drug that “reaches surgery-level weight loss.” The weight-loss outcomes reported by the company for the experimental drug — a GLP-1, GIP, and glucagon agonist — are impressive. Depending on the trial, participants on the highest

Medscape — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape

Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix - Medscape Source: Medscape Published: Thu, 22 Oct 2026 09:02:22 GMT Recent headlines hail Eli Lilly’s triple agonist retatrutide as “the most powerful weight-loss drug ever tested,” a “new high-water mark,” and a drug that “reaches surgery-level weight loss.” The weight-loss outcomes reported by the company for the experimental drug — a GLP-1, GIP, and glucagon agonist — are impressive. Depending on the trial, participants on the highest

PubMed — Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of

BACKGROUND: GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes. METHODS: We did a meta-analysis, including new data from AMPL

PubMed — Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, rand

BACKGROUND: Given the unique phenotype of type 2 diabetes in Japanese patients, novel therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed to assess the dose-response of oral semaglutide and to compare the efficacy and safety of oral semaglutide with placebo and a subcutaneous GLP-1 receptor agonist in a Japanese population. METHODS: PIONEER 9 was a 52-week, phase 2/3a, randomised, controlled trial done at 16 sites (clinics and university hospitals) in

Google News (Quora Q&A search) — How does appetite reduction caused by GLP-1 medications affect the risk of Werni

Quora Q&A: How does appetite reduction caused by GLP-1 medications affect the risk of Wernicke encephalopathy? - Quora Published: Sun, 13 Sep 2026 07:00:00 GMT How does appetite reduction caused by GLP-1 medications affect the risk of Wernicke encephalopathy?  Quora

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Fatigue

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Fatigue occurred in 10 participants (4.1%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Fatigue

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Fatigue occurred in 3 participants (1.2%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Fatigue

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Fatigue occurred in 5 participants (2.1%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Vomiting

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Vomiting occurred in 29 participants (12.0%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Vomiting

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Vomiting occurred in 20 participants (8.3%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Vomiting

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Vomiting occurred in 19 participants (7.9%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Nausea

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Nausea occurred in 54 participants (22.4%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Nausea

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Nausea occurred in 43 participants (17.8%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Nausea

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Nausea occurred in 47 participants (19.6%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Gastrooesophageal reflux disease

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Gastrooesophageal reflux disease occurred in 14 participants (5.8%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Gastrooesophageal reflux disease

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Gastrooesophageal reflux disease occurred in 6 participants (2.5%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Gastrooesophageal reflux disease

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Gastrooesophageal reflux disease occurred in 7 participants (2.9%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Diarrhoea

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Diarrhoea occurred in 48 participants (19.9%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Diarrhoea

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Diarrhoea occurred in 40 participants (16.6%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Diarrhoea

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Diarrhoea occurred in 44 participants (18.3%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Constipation

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Constipation occurred in 25 participants (10.4%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Constipation

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Constipation occurred in 20 participants (8.3%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Constipation

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Constipation occurred in 19 participants (7.9%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Abdominal pain

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 36 mg" arm (n=241 at risk), Abdominal pain occurred in 6 participants (2.5%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Abdominal pain

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 12 mg" arm (n=241 at risk), Abdominal pain occurred in 9 participants (3.7%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) Compared With… — Abdominal pain

Posted trial results for A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108, PHASE3). In the "Orforglipron 3 mg" arm (n=240 at risk), Abdominal pain occurred in 9 participants (3.8%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline Up to Week 42

PubMed — Gastroparesis: A Review.

IMPORTANCE: Gastroparesis is a condition of delayed gastric emptying in the absence of gastric outlet obstruction. Based on a 2018 US administrative health insurance claims database study, prevalence of definite gastroparesis (with documented delayed gastric emptying) was 21.5 per 100 000 persons. OBSERVATIONS: Gastroparesis, which is caused by reduced contractions of the distal stomach or abnormal pyloric relaxation, is more common among females than males (ratio, 2:1-4:1) and typically c

PubMed — Gastroparesis: A Review.

IMPORTANCE: Gastroparesis is a condition of delayed gastric emptying in the absence of gastric outlet obstruction. Based on a 2018 US administrative health insurance claims database study, prevalence of definite gastroparesis (with documented delayed gastric emptying) was 21.5 per 100 000 persons. OBSERVATIONS: Gastroparesis, which is caused by reduced contractions of the distal stomach or abnormal pyloric relaxation, is more common among females than males (ratio, 2:1-4:1) and typically c

PubMed — Gastroparesis: A Review.

IMPORTANCE: Gastroparesis is a condition of delayed gastric emptying in the absence of gastric outlet obstruction. Based on a 2018 US administrative health insurance claims database study, prevalence of definite gastroparesis (with documented delayed gastric emptying) was 21.5 per 100 000 persons. OBSERVATIONS: Gastroparesis, which is caused by reduced contractions of the distal stomach or abnormal pyloric relaxation, is more common among females than males (ratio, 2:1-4:1) and typically c

Google News (X/Twitter search) — I see so many patients suffering Mounjaro cramps. It's such a cruel, debilitatin

Tweet/X post: I see so many patients suffering Mounjaro cramps. It's such a cruel, debilitating side effect. This is how to fix it - and why dosage, food triggers and WHEN you inject is so important: DR ELLIE CANNON https://t.co/TdBWwEgqU4 - X Published: Sat, 17 Oct 2026 12:29:56 GMT I see so many patients suffering Mounjaro cramps. It's such a cruel, debilitating side effect. This is how to fix it - and why dosage, food triggers and WHEN you inject is so important: DR ELLIE CANNON https://t.c

PubMed — CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systema

INTRODUCTION: Semaglutide 2.4 mg is the reference pharmacotherapy for weight management, yet many patients do not reach ambitious weight-loss targets. CagriSema, a fixed-dose combination of cagrilintide and semaglutide, may offer additional benefit through complementary mechanisms. We quantified its incremental efficacy and safety against semaglutide 2.4 mg monotherapy in adults with overweight or obesity, with and without type 2 diabetes. METHODS: This PRISMA 2020-compliant review (PROSPE

PubMed — Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

BACKGROUND: Obesity is a worldwide health concern linked to cardiometabolic comorbidities such as type 2 diabetes, hypertension, dyslipidemia, and heart disease. The management of obesity using pharmacotherapy, especially with GLP-1 receptor agonists and dual incretin agents, has proven successful not only for weight loss but also for gaining control of the metabolic components of the disease. Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometab

PubMed — Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

BACKGROUND: Obesity is a worldwide health concern linked to cardiometabolic comorbidities such as type 2 diabetes, hypertension, dyslipidemia, and heart disease. The management of obesity using pharmacotherapy, especially with GLP-1 receptor agonists and dual incretin agents, has proven successful not only for weight loss but also for gaining control of the metabolic components of the disease. Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometab

PubMed — Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

BACKGROUND: Obesity is a worldwide health concern linked to cardiometabolic comorbidities such as type 2 diabetes, hypertension, dyslipidemia, and heart disease. The management of obesity using pharmacotherapy, especially with GLP-1 receptor agonists and dual incretin agents, has proven successful not only for weight loss but also for gaining control of the metabolic components of the disease. Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometab

PubMed — Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

BACKGROUND: Obesity is a worldwide health concern linked to cardiometabolic comorbidities such as type 2 diabetes, hypertension, dyslipidemia, and heart disease. The management of obesity using pharmacotherapy, especially with GLP-1 receptor agonists and dual incretin agents, has proven successful not only for weight loss but also for gaining control of the metabolic components of the disease. Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometab

PubMed — Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

BACKGROUND: Obesity is a worldwide health concern linked to cardiometabolic comorbidities such as type 2 diabetes, hypertension, dyslipidemia, and heart disease. The management of obesity using pharmacotherapy, especially with GLP-1 receptor agonists and dual incretin agents, has proven successful not only for weight loss but also for gaining control of the metabolic components of the disease. Thus, it is pertinent to analyse the GLP-1-based anti-obesity medications to examine cardiometab

The Guardian (MHRA-safety search) — Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warn

Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns - The Guardian Source: The Guardian Published: Thu, 29 Jan 2026 08:00:00 GMT Agency updates guidance after increase in reports of condition to its yellow card scheme Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said. About 1.6 million adults in England, Wales and Scotland used GLP-1 medication,

The Guardian (MHRA-safety search) — Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warn

Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns - The Guardian Source: The Guardian Published: Thu, 29 Jan 2026 08:00:00 GMT Agency updates guidance after increase in reports of condition to its yellow card scheme Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said. About 1.6 million adults in England, Wales and Scotland used GLP-1 medication,

The Guardian (MHRA-safety search) — Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warn

Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns - The Guardian Source: The Guardian Published: Thu, 29 Jan 2026 08:00:00 GMT Agency updates guidance after increase in reports of condition to its yellow card scheme Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said. About 1.6 million adults in England, Wales and Scotland used GLP-1 medication,

PubMed India — Characterizing the adverse event profile of semaglutide: A comprehensive U.S. fo

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the management of type 2 diabetes mellitus and obesity. Given its expanding clinical use, a comprehensive evaluation of its safety profile using real-world data is warranted. This study aimed to characterize adverse event signals associated with semaglutide using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Adverse event reports associated with semaglutide

PubMed India — Characterizing the adverse event profile of semaglutide: A comprehensive U.S. fo

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the management of type 2 diabetes mellitus and obesity. Given its expanding clinical use, a comprehensive evaluation of its safety profile using real-world data is warranted. This study aimed to characterize adverse event signals associated with semaglutide using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Adverse event reports associated with semaglutide

PubMed India — Characterizing the adverse event profile of semaglutide: A comprehensive U.S. fo

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the management of type 2 diabetes mellitus and obesity. Given its expanding clinical use, a comprehensive evaluation of its safety profile using real-world data is warranted. This study aimed to characterize adverse event signals associated with semaglutide using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Adverse event reports associated with semaglutide

PubMed India — Characterizing the adverse event profile of semaglutide: A comprehensive U.S. fo

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the management of type 2 diabetes mellitus and obesity. Given its expanding clinical use, a comprehensive evaluation of its safety profile using real-world data is warranted. This study aimed to characterize adverse event signals associated with semaglutide using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Adverse event reports associated with semaglutide

PubMed India — Characterizing the adverse event profile of semaglutide: A comprehensive U.S. fo

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the management of type 2 diabetes mellitus and obesity. Given its expanding clinical use, a comprehensive evaluation of its safety profile using real-world data is warranted. This study aimed to characterize adverse event signals associated with semaglutide using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: Adverse event reports associated with semaglutide

Medical News Today (EMA-safety search) — Does Mounjaro cause depression? Research, causes, and what to do - Medical News

Does Mounjaro cause depression? Research, causes, and what to do - Medical News Today Source: Medical News Today Published: Tue, 10 Feb 2026 08:00:00 GMT Research has not shown a link between Mounjaro (tirzepatide) and depression, but anecdotal reports suggest mood changes are possible. Mounjaro is a GLP-1 medication originally approved for type 2 diabetes. It is also a popular option for weight loss because it helps regulate blood sugar and reduces appetite. While the physical results can b

Google News (X/Twitter search) — Manage GLP-1 side effects like nausea & fatigue! Check out InShapeMD's 5 strateg

Tweet/X post: Manage GLP-1 side effects like nausea & fatigue! Check out InShapeMD's 5 strategies for success with Semaglutide, Tirzepatide & more." https://t.co/IfVWQXqTm8 - X Published: Fri, 17 Jan 2025 08:00:00 GMT Manage GLP-1 side effects like nausea & fatigue! Check out InShapeMD's 5 strategies for success with Semaglutide, Tirzepatide & more." https://t.co/IfVWQXqTm8  X

Google News (X/Twitter search) — Manage GLP-1 side effects like nausea & fatigue! Check out InShapeMD's 5 strateg

Tweet/X post: Manage GLP-1 side effects like nausea & fatigue! Check out InShapeMD's 5 strategies for success with Semaglutide, Tirzepatide & more." https://t.co/IfVWQXqTm8 - X Published: Fri, 17 Jan 2025 08:00:00 GMT Manage GLP-1 side effects like nausea & fatigue! Check out InShapeMD's 5 strategies for success with Semaglutide, Tirzepatide & more." https://t.co/IfVWQXqTm8  X

BigGo Finance (EMA-safety search) — Eli Lilly Looks Beyond Mounjaro to Cement Obesity Drug Dominance with Triple Ago

Eli Lilly Looks Beyond Mounjaro to Cement Obesity Drug Dominance with Triple Agonist - BigGo Finance Source: BigGo Finance Published: Wed, 14 Oct 2026 06:35:00 GMT Eli Lilly is accelerating development of a triple agonist aimed at the next-generation obesity treatment market. Having already secured the top spot in the global market with its blockbuster obesity drug Mounjaro, the company's strategy is to extend its competitive edge with a next-generation pipeline capable of delivering even grea

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Dizziness

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Dizziness occurred in 3 participants (2.6%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Nausea

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Nausea occurred in 6 participants (5.3%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Dizziness

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Dizziness occurred in 15 participants (4.5%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

PubMed — Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

AIMS: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. MATERIALS AND METHODS: We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c. Secondary endpoints included change from baseline in body weight, blood pressure, heart rate and incidence

PubMed — Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

AIMS: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. MATERIALS AND METHODS: We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c. Secondary endpoints included change from baseline in body weight, blood pressure, heart rate and incidence

PubMed — Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

AIMS: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. MATERIALS AND METHODS: We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c. Secondary endpoints included change from baseline in body weight, blood pressure, heart rate and incidence

PubMed — Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

AIMS: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. MATERIALS AND METHODS: We searched major electronic databases and grey literature sources for randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c. Secondary endpoints included change from baseline in body weight, blood pressure, heart rate and incidence

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Vomiting

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Vomiting occurred in 2 participants (2.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Nausea

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Nausea occurred in 4 participants (4.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Headache

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Headache occurred in 3 participants (3.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Dizziness

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Dizziness occurred in 0 participants (0.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Diarrhoea

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Diarrhoea occurred in 6 participants (5.9%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Decreased appetite

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Decreased appetite occurred in 0 participants (0.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Constipation

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Constipation occurred in 3 participants (3.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — STEP 6: Research Study Investigating How Well Semaglutide… — Abdominal pain

Posted trial results for STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (NCT03811574, PHASE3). In the "Placebo" arm (n=101 at risk), Abdominal pain occurred in 0 participants (0.0%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 75.

ClinicalTrials.gov results — Research Study Looking at How Well Semaglutide Works in… — Vomiting

Posted trial results for Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (NCT05064735, PHASE3). In the "Placebo" arm (n=135 at risk), Vomiting occurred in 1 participants (0.7%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 75)

ClinicalTrials.gov results — Research Study Looking at How Well Semaglutide Works in… — Nausea

Posted trial results for Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (NCT05064735, PHASE3). In the "Placebo" arm (n=135 at risk), Nausea occurred in 12 participants (8.9%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 75)

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Abdominal Pain

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Abdominal Pain occurred in 3 participants (1.4%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and incr

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Nausea

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Nausea occurred in 36 participants (17.1%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and increasing

ClinicalTrials.gov results — 24-week Treatment With Lixisenatide in Type 2 Diabetes… — Dizziness

Posted trial results for 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (NCT00975286, PHASE3). In the "Placebo" arm (n=223 at risk), Dizziness occurred in 6 participants (2.7%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Dizziness

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Dizziness occurred in 2 participants (1.7%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Decreased appetite

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Decreased appetite occurred in 3 participants (2.6%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Decreased appetite

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Decreased appetite occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Injection site reaction

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Injection site reaction occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Injection site reaction

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Injection site reaction occurred in 1 participants (0.8%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Abdominal pain

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Abdominal pain occurred in 2 participants (1.8%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Versus Placebo in… — Diarrhoea

Posted trial results for A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (NCT04039503, PHASE3). In the "Placebo" arm (n=120 at risk), Diarrhoea occurred in 12 participants (10.0%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline, 17 Months

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Headache

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834, PHASE3). In the "Placebo" arm (n=115 at risk), Headache occurred in 9 participants (7.8%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of Safety follow-up (up to 44 weeks)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Nausea

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834, PHASE3). In the "Placebo" arm (n=115 at risk), Nausea occurred in 7 participants (6.1%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of Safety follow-up (up to 44 weeks)

ClinicalTrials.gov results — A Study of LY3437943 in Participants Who Have Obesity or… — Dizziness

Posted trial results for A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760, PHASE2). In the "Placebo" arm (n=70 at risk), Dizziness occurred in 2 participants (2.9%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Through End of Safety Follow-up (Up to 52 Weeks)

ClinicalTrials.gov results — Research Study Looking at How Well Semaglutide Works in… — Headache

Posted trial results for Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (NCT05064735, PHASE3). In the "Placebo" arm (n=135 at risk), Headache occurred in 5 participants (3.7%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 75)

ClinicalTrials.gov results — Research Study Looking at How Well Semaglutide Works in… — Diarrhoea

Posted trial results for Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (NCT05064735, PHASE3). In the "Placebo" arm (n=135 at risk), Diarrhoea occurred in 7 participants (5.2%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 75)

ClinicalTrials.gov results — Research Study Looking at How Well Semaglutide Works in… — Constipation

Posted trial results for Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (NCT05064735, PHASE3). In the "Placebo" arm (n=135 at risk), Constipation occurred in 7 participants (5.2%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 75)

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Decreased Appetite

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Decreased Appetite occurred in 3 participants (1.4%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Fatigue

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Fatigue occurred in 11 participants (5.2%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and increasing

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Dizziness

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Dizziness occurred in 18 participants (8.6%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and increasi

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Headache

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Headache occurred in 26 participants (12.4%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and increasi

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Vomiting

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Vomiting occurred in 5 participants (2.4%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and increasing

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Diarrhoea

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Diarrhoea occurred in 26 participants (12.4%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and increas

ClinicalTrials.gov results — Comparison of Liraglutide Versus Placebo in Weight Loss… — Constipation

Posted trial results for Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937, PHASE3). In the "Placebo" arm (n=210 at risk), Constipation occurred in 26 participants (12.4%). Conditions: Metabolism and Nutrition Disorder, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Treatment emergent adverse events were defined as occurring before randomisation and incr

ClinicalTrials.gov results — A Study of Dulaglutide (LY2189265) in Participants With… — Headache

Posted trial results for A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (NCT02597049, PHASE3). In the "Placebo" arm (n=140 at risk), Headache occurred in 13 participants (9.3%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of study (up to 24 weeks)

ClinicalTrials.gov results — A Study of Dulaglutide (LY2189265) in Participants With… — Nausea

Posted trial results for A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (NCT02597049, PHASE3). In the "Placebo" arm (n=140 at risk), Nausea occurred in 5 participants (3.6%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of study (up to 24 weeks)

ClinicalTrials.gov results — A Study of Dulaglutide (LY2189265) in Participants With… — Diarrhoea

Posted trial results for A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (NCT02597049, PHASE3). In the "Placebo" arm (n=140 at risk), Diarrhoea occurred in 4 participants (2.9%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of study (up to 24 weeks)

ClinicalTrials.gov results — 24-week Treatment With Lixisenatide in Type 2 Diabetes… — Vomiting

Posted trial results for 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (NCT00975286, PHASE3). In the "Placebo" arm (n=223 at risk), Vomiting occurred in 3 participants (1.3%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration

ClinicalTrials.gov results — 24-week Treatment With Lixisenatide in Type 2 Diabetes… — Nausea

Posted trial results for 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (NCT00975286, PHASE3). In the "Placebo" arm (n=223 at risk), Nausea occurred in 11 participants (4.9%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration

ClinicalTrials.gov results — 24-week Treatment With Lixisenatide in Type 2 Diabetes… — Diarrhoea

Posted trial results for 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (NCT00975286, PHASE3). In the "Placebo" arm (n=223 at risk), Diarrhoea occurred in 7 participants (3.1%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration

ClinicalTrials.gov results — 24-week Treatment With Lixisenatide in Type 2 Diabetes… — Headache

Posted trial results for 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (NCT00975286, PHASE3). In the "Placebo" arm (n=223 at risk), Headache occurred in 8 participants (3.6%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration

ClinicalTrials.gov results — The Effect of Liraglutide Versus Placebo When Added to… — Headache

Posted trial results for The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes (NCT01617434, PHASE3). In the "Placebo" arm (n=225 at risk), Headache occurred in 16 participants (7.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to Week 26 + 7 days follow up

ClinicalTrials.gov results — The Effect of Liraglutide Versus Placebo When Added to… — Decreased appetite

Posted trial results for The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes (NCT01617434, PHASE3). In the "Placebo" arm (n=225 at risk), Decreased appetite occurred in 5 participants (2.2%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to Week 26 + 7 days follow up

ClinicalTrials.gov results — The Effect of Liraglutide Versus Placebo When Added to… — Vomiting

Posted trial results for The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes (NCT01617434, PHASE3). In the "Placebo" arm (n=225 at risk), Vomiting occurred in 2 participants (0.9%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to Week 26 + 7 days follow up

ClinicalTrials.gov results — The Effect of Liraglutide Versus Placebo When Added to… — Nausea

Posted trial results for The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes (NCT01617434, PHASE3). In the "Placebo" arm (n=225 at risk), Nausea occurred in 7 participants (3.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to Week 26 + 7 days follow up

ClinicalTrials.gov results — The Effect of Liraglutide Versus Placebo When Added to… — Diarrhoea

Posted trial results for The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes (NCT01617434, PHASE3). In the "Placebo" arm (n=225 at risk), Diarrhoea occurred in 11 participants (4.9%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to Week 26 + 7 days follow up

ClinicalTrials.gov results — Phase III Study to Evaluate Safety and Efficacy of Added… — Nausea

Posted trial results for Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus (NCT02229383, PHASE3). In the "Placebo" arm (n=229 at risk), Nausea occurred in 9 participants (3.9%). Conditions: Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Baseline (Day 1) up to Week 28

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Alopecia

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Alopecia occurred in 1 participants (0.9%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Alopecia

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Alopecia occurred in 1 participants (0.8%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Headache

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Headache occurred in 1 participants (0.9%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Headache

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Headache occurred in 3 participants (2.5%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Cholelithiasis

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Cholelithiasis occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Cholelithiasis

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Cholelithiasis occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Fatigue

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Fatigue occurred in 1 participants (0.9%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Fatigue

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Fatigue occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Vomiting

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Vomiting occurred in 1 participants (0.9%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Vomiting

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Vomiting occurred in 5 participants (4.2%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Pancreatitis acute

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Pancreatitis acute occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Pancreatitis acute

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Pancreatitis acute occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Nausea

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Nausea occurred in 12 participants (10.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Gastrooesophageal reflux disease

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Gastrooesophageal reflux disease

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Gastrooesophageal reflux disease occurred in 1 participants (0.8%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Diarrhoea

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Diarrhoea occurred in 10 participants (8.8%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Diarrhoea

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Diarrhoea occurred in 15 participants (12.5%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Constipation

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI2" arm (n=114 at risk), Constipation occurred in 5 participants (4.4%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Constipation

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Constipation occurred in 3 participants (2.5%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — Obstructive Sleep Apnea Master Protocol GPIF: A Study of… — Abdominal pain

Posted trial results for Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (NCT05412004, PHASE3). In the "Placebo_GPI1" arm (n=120 at risk), Abdominal pain occurred in 4 participants (3.3%). Conditions: Obstructive Sleep Apnea, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 0. AE counting window: Baseline to Follow-up (Up To 56 Weeks)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Versus Placebo in… — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (NCT04039503, PHASE3). In the "Placebo" arm (n=120 at risk), Decreased appetite occurred in 2 participants (1.7%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline, 17 Months

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Versus Placebo in… — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (NCT04039503, PHASE3). In the "Placebo" arm (n=120 at risk), Vomiting occurred in 3 participants (2.5%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline, 17 Months

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Versus Placebo in… — Nausea

Posted trial results for A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (NCT04039503, PHASE3). In the "Placebo" arm (n=120 at risk), Nausea occurred in 3 participants (2.5%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline, 17 Months

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Versus Placebo in… — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (NCT04039503, PHASE3). In the "Placebo" arm (n=120 at risk), Constipation occurred in 2 participants (1.7%). Conditions: Type 2 Diabetes. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline, 17 Months

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834, PHASE3). In the "Placebo" arm (n=115 at risk), Decreased appetite occurred in 1 participants (0.9%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of Safety follow-up (up to 44 weeks)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834, PHASE3). In the "Placebo" arm (n=115 at risk), Vomiting occurred in 2 participants (1.7%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of Safety follow-up (up to 44 weeks)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Diarrhoea

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834, PHASE3). In the "Placebo" arm (n=115 at risk), Diarrhoea occurred in 9 participants (7.8%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of Safety follow-up (up to 44 weeks)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834, PHASE3). In the "Placebo" arm (n=115 at risk), Constipation occurred in 1 participants (0.9%). Conditions: Type 2 Diabetes Mellitus. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline to end of Safety follow-up (up to 44 weeks)

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Fatigue

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815, PHASE3). In the "Placebo" arm (n=161 at risk), Fatigue occurred in 3 participants (1.9%). Conditions: Diabetes Mellitus Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up to 1

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Vomiting

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815, PHASE3). In the "Placebo" arm (n=161 at risk), Vomiting occurred in 8 participants (5.0%). Conditions: Diabetes Mellitus Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up to

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Nausea

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815, PHASE3). In the "Placebo" arm (n=161 at risk), Nausea occurred in 22 participants (13.7%). Conditions: Diabetes Mellitus Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up to

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Headache

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815, PHASE3). In the "Placebo" arm (n=161 at risk), Headache occurred in 19 participants (11.8%). Conditions: Diabetes Mellitus Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up t

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Diarrhoea

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (NCT00715624, PHASE3). In the "Placebo" arm (n=167 at risk), Diarrhoea occurred in 10 participants (6.0%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration for up

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Diarrhoea

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Diarrhoea occurred in 9 participants (8.8%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study Comparing a New Medicine Oral Semaglutide… — Decreased appetite

Posted trial results for A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (NCT04109547, PHASE3). In the "Placebo" arm (n=131 at risk), Decreased appetite occurred in 0 participants (0.0%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 31

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Gastrooesophageal reflux disease

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Gastrooesophageal reflux disease occurred in 11 participants (3.3%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Constipation

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (NCT03021187, PHASE3). In the "Placebo" arm (n=184 at risk), Constipation occurred in 5 participants (2.7%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are b

ClinicalTrials.gov results — Evaluation of Cardiovascular Outcomes in Patients With Type… — Vomiting

Posted trial results for Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (NCT01147250, PHASE3). In the "Placebo" arm (n=3032 at risk), Vomiting occurred in 82 participants (2.7%). Conditions: Acute Coronary Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: All Adverse Events (AEs) were collected from signature of the informed co

ClinicalTrials.gov results — A Study of LY3437943 in Participants Who Have Obesity or… — Vomiting

Posted trial results for A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760, PHASE2). In the "Placebo" arm (n=70 at risk), Vomiting occurred in 1 participants (1.4%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Through End of Safety Follow-up (Up to 52 Weeks)

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Headache

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Headache occurred in 3 participants (7.0%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Decreased appetite

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Decreased appetite occurred in 2 participants (4.7%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Fatigue

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Fatigue occurred in 2 participants (4.7%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Vomiting

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Vomiting occurred in 0 participants (0.0%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Nausea

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Nausea occurred in 2 participants (4.7%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Gastrooesophageal reflux disease

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Diarrhoea

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Diarrhoea occurred in 3 participants (7.0%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

ClinicalTrials.gov results — Phase 2a Placebo-Controlled Study of VTX3232 Alone or in… — Constipation

Posted trial results for Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (NCT06771115, PHASE2). In the "Placebo" arm (n=43 at risk), Constipation occurred in 3 participants (7.0%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline to Week 16

Yahoo Health — 'Ozempic babies' are real — here's what doctors want you to know about fertility

'Ozempic babies' are real — here's what doctors want you to know about fertility and GLP-1 drugs - Yahoo Health Source: Yahoo Health Published: Fri, 09 Oct 2026 15:00:00 GMT Our experts independently review everything we recommend. If you buy through our links, we may earn commission. "Ozempic babies" has become the internet's shorthand for surprise pregnancies among people taking GLP-1 drugs like Ozempic and Wegovy. Scroll TikTok and you'll find plenty of people sharing their positive pregna

Yahoo Health — 'Ozempic babies' are real — here's what doctors want you to know about fertility

'Ozempic babies' are real — here's what doctors want you to know about fertility and GLP-1 drugs - Yahoo Health Source: Yahoo Health Published: Fri, 09 Oct 2026 15:00:00 GMT Our experts independently review everything we recommend. If you buy through our links, we may earn commission. "Ozempic babies" has become the internet's shorthand for surprise pregnancies among people taking GLP-1 drugs like Ozempic and Wegovy. Scroll TikTok and you'll find plenty of people sharing their positive pregna

SciTechDaily — Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Tr

Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial - SciTechDaily Source: SciTechDaily Published: Mon, 12 Oct 2026 13:45:10 GMT Retatrutide could help tackle obesity and type 2 diabetes together, with an 80-week trial showing substantial weight loss and better blood sugar control alongside more nausea and diarrhea. A weekly injection beneath the skin helped adults with excess weight and type 2 diabetes lose nearly a fifth of their starting weight, on average,

SciTechDaily — Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Tr

Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial - SciTechDaily Source: SciTechDaily Published: Mon, 12 Oct 2026 13:45:10 GMT Retatrutide could help tackle obesity and type 2 diabetes together, with an 80-week trial showing substantial weight loss and better blood sugar control alongside more nausea and diarrhea. A weekly injection beneath the skin helped adults with excess weight and type 2 diabetes lose nearly a fifth of their starting weight, on average,

Pharmacy Times (WHO-safety search) — Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Ph

Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring - Pharmacy Times Source: Pharmacy Times Published: Thu, 08 Oct 2026 21:15:24 GMT Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring  Pharmacy Times

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2… — Headache

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "Placebo QD - Part B" arm (n=11 at risk), Headache occurred in 1 participants (9.1%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Through Follow-Up (Up To Week 15)

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A Placebo" arm (n=8 at risk), Headache occurred in 0 participants (0.0%). Conditions: Healthy. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Follow-up (up to Day 42)

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B Placebo QD" arm (n=15 at risk), Constipation occurred in 0 participants (0.0%). Conditions: Healthy. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Follow-up (up to Day 42)

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Diarrhoea

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815, PHASE3). In the "Placebo" arm (n=161 at risk), Diarrhoea occurred in 23 participants (14.3%). Conditions: Diabetes Mellitus Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Dizziness

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815, PHASE3). In the "Placebo" arm (n=161 at risk), Dizziness occurred in 13 participants (8.1%). Conditions: Diabetes Mellitus Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up t

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Vomiting

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (NCT00715624, PHASE3). In the "Placebo" arm (n=167 at risk), Vomiting occurred in 2 participants (1.2%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration for up to

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Nausea

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (NCT00715624, PHASE3). In the "Placebo" arm (n=167 at risk), Nausea occurred in 16 participants (9.6%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration for up to

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Headache

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (NCT00715624, PHASE3). In the "Placebo" arm (n=167 at risk), Headache occurred in 17 participants (10.2%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration for up

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Dizziness

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (NCT00715624, PHASE3). In the "Placebo" arm (n=167 at risk), Dizziness occurred in 11 participants (6.6%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration for up

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Vomiting

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Vomiting occurred in 3 participants (2.9%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Nausea

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Nausea occurred in 12 participants (11.8%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Headache

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Headache occurred in 4 participants (3.9%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Fatigue

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Fatigue occurred in 5 participants (4.9%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Decreased appetite

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Decreased appetite occurred in 5 participants (4.9%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Constipation

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Constipation occurred in 5 participants (4.9%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Abdominal pain

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (NCT05649137, PHASE3). In the "Placebo" arm (n=102 at risk), Abdominal pain occurred in 3 participants (2.9%). Conditions: Obesity, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 81

ClinicalTrials.gov results — A Research Study Comparing a New Medicine Oral Semaglutide… — Nausea

Posted trial results for A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (NCT04109547, PHASE3). In the "Placebo" arm (n=131 at risk), Nausea occurred in 2 participants (1.5%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 31

ClinicalTrials.gov results — A Research Study Comparing a New Medicine Oral Semaglutide… — Diarrhoea

Posted trial results for A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (NCT04109547, PHASE3). In the "Placebo" arm (n=131 at risk), Diarrhoea occurred in 2 participants (1.5%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 31

ClinicalTrials.gov results — A Research Study Comparing a New Medicine Oral Semaglutide… — Constipation

Posted trial results for A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (NCT04109547, PHASE3). In the "Placebo" arm (n=131 at risk), Constipation occurred in 0 participants (0.0%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From week 0 to week 31

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Works in… — Vomiting

Posted trial results for Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (NCT04788511, PHASE3). In the "Placebo" arm (n=266 at risk), Vomiting occurred in 3 participants (1.1%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 57)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Works in… — Nausea

Posted trial results for Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (NCT04788511, PHASE3). In the "Placebo" arm (n=266 at risk), Nausea occurred in 7 participants (2.6%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 57)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Works in… — Diarrhoea

Posted trial results for Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (NCT04788511, PHASE3). In the "Placebo" arm (n=266 at risk), Diarrhoea occurred in 10 participants (3.8%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 57)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Works in… — Constipation

Posted trial results for Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (NCT04788511, PHASE3). In the "Placebo" arm (n=266 at risk), Constipation occurred in 7 participants (2.6%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of trial (week 57)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Alopecia

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Alopecia occurred in 4 participants (1.4%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Headache

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Headache occurred in 22 participants (7.5%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Dizziness

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Dizziness occurred in 6 participants (2.1%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Decreased appetite occurred in 12 participants (4.1%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Injection site reaction

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Injection site reaction occurred in 3 participants (1.0%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Fatigue

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Fatigue occurred in 9 participants (3.1%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Vomiting occurred in 4 participants (1.4%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Nausea

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Nausea occurred in 41 participants (14.0%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Gastrooesophageal reflux disease

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Gastrooesophageal reflux disease occurred in 7 participants (2.4%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Diarrhoea

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Diarrhoea occurred in 27 participants (9.2%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Constipation occurred in 20 participants (6.8%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) In Participants After A… — Abdominal pain

Posted trial results for A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (NCT04657016, PHASE3). In the "Placebo" arm (n=292 at risk), Abdominal pain occurred in 7 participants (2.4%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to week 76

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Vomiting

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Vomiting occurred in 12 participants (3.6%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Nausea

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Nausea occurred in 51 participants (15.3%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Headache

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Headache occurred in 29 participants (8.7%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Fatigue

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Fatigue occurred in 20 participants (6.0%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Diarrhoea

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Diarrhoea occurred in 56 participants (16.8%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Decreased appetite

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Decreased appetite occurred in 24 participants (7.2%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Constipation

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Constipation occurred in 50 participants (15.0%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Alopecia

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Alopecia occurred in 9 participants (2.7%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets… — Abdominal pain

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) (NCT05035095, PHASE3). In the "Placebo" arm (n=333 at risk), Abdominal pain occurred in 16 participants (4.8%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end-of-study (week 75)

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Vomiting

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (NCT02906930, PHASE3). In the "Placebo" arm (n=178 at risk), Vomiting occurred in 4 participants (2.2%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 31 (26 weeks treatment period + 5 weeks follow-up period). Re

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Nausea

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (NCT02906930, PHASE3). In the "Placebo" arm (n=178 at risk), Nausea occurred in 10 participants (5.6%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 31 (26 weeks treatment period + 5 weeks follow-up period). Res

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Headache

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (NCT02906930, PHASE3). In the "Placebo" arm (n=178 at risk), Headache occurred in 9 participants (5.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 31 (26 weeks treatment period + 5 weeks follow-up period). Re

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Diarrhoea

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (NCT02906930, PHASE3). In the "Placebo" arm (n=178 at risk), Diarrhoea occurred in 4 participants (2.2%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 31 (26 weeks treatment period + 5 weeks follow-up period). R

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557, PHASE3). In the "Placebo" arm (n=367 at risk), Vomiting occurred in 7 participants (1.9%). Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF). Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up To 162 Weeks

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557, PHASE3). In the "Placebo" arm (n=367 at risk), Constipation occurred in 22 participants (6.0%). Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF). Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up To 162 Weeks

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Nausea

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830, PHASE3). In the "Placebo" arm (n=285 at risk), Nausea occurred in 25 participants (8.8%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up to

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Diarrhoea

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830, PHASE3). In the "Placebo" arm (n=285 at risk), Diarrhoea occurred in 27 participants (9.5%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Headache

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830, PHASE3). In the "Placebo" arm (n=285 at risk), Headache occurred in 20 participants (7.0%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up t

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Headache

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Headache occurred in 40 participants (11.5%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Abdominal pain

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Abdominal pain occurred in 8 participants (2.3%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — Evaluation of Cardiovascular Outcomes in Patients With Type… — Dizziness

Posted trial results for Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (NCT01147250, PHASE3). In the "Placebo" arm (n=3032 at risk), Dizziness occurred in 191 participants (6.3%). Conditions: Acute Coronary Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: All Adverse Events (AEs) were collected from signature of the informed

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Vomiting

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Vomiting occurred in 154 participants (3.1%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Headache

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Headache occurred in 9 participants (2.9%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Decreased appetite occurred in 7 participants (2.2%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Vomiting occurred in 10 participants (3.2%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Constipation occurred in 13 participants (4.1%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Headache

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Headache occurred in 71 participants (7.5%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Decreased appetite

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Decreased appetite occurred in 30 participants (3.2%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Nausea

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Nausea occurred in 99 participants (10.4%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Diarrhoea

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Diarrhoea occurred in 91 participants (9.6%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Constipation

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Constipation occurred in 88 participants (9.3%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Vomiting

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (NCT05646706, PHASE3). In the "Placebo" arm (n=201 at risk), Vomiting occurred in 14 participants (7.0%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of study (week 81)

ClinicalTrials.gov results — A Research Study to See How Semaglutide Helps People With… — Headache

Posted trial results for A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (NCT05646706, PHASE3). In the "Placebo" arm (n=201 at risk), Headache occurred in 17 participants (8.5%). Conditions: Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From baseline (week 0) to end of study (week 81)

ClinicalTrials.gov results — Research Study to Look at How Well Semaglutide is at… — Vomiting

Posted trial results for Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (NCT03611582, PHASE3). In the "Placebo" arm (n=204 at risk), Vomiting occurred in 22 participants (10.8%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: week 0 to week 75 Results are based on the SAS which included all participants who received at lea

ClinicalTrials.gov results — A Study of LY3437943 in Participants Who Have Obesity or… — Abdominal pain

Posted trial results for A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760, PHASE2). In the "Placebo" arm (n=70 at risk), Abdominal pain occurred in 2 participants (2.9%). Conditions: Obesity, Overweight. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Through End of Safety Follow-up (Up to 52 Weeks)

ClinicalTrials.gov results — STEP 1: Research Study Investigating How Well Semaglutide… — Vomiting

Posted trial results for STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (NCT03548935, PHASE3). In the "Placebo" arm (n=655 at risk), Vomiting occurred in 43 participants (6.6%). Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: week 0 to week 75 Results are based on the SAS which included all participan

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Dizziness

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (NCT04184622, PHASE3). In the "Placebo" arm (n=643 at risk), Dizziness occurred in 16 participants (2.5%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to Week 193

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Injection site reaction

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (NCT04184622, PHASE3). In the "Placebo" arm (n=643 at risk), Injection site reaction occurred in 2 participants (0.3%). Conditions: Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline up to Week 193

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

MIT Technology Review — We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Techn

We’re still figuring out the side effects of GLP-1 weight-loss drugs - MIT Technology Review Source: MIT Technology Review Published: Fri, 09 Oct 2026 09:00:00 GMT This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than

Yahoo Creators — Feeling awful on your GLP-1? The drug may not be what's making you miserable - Y

Feeling awful on your GLP-1? The drug may not be what's making you miserable - Yahoo Creators Source: Yahoo Creators Published: Sun, 11 Oct 2026 20:24:43 GMT Most people who start taking a GLP-1 medication aren't taking it a year later. The gap between the expectations and reality is startling for many patients, and the numbers might surprise you. For instance, a cohort study of more than 125,000 adults published in JAMA Network Open found that 46.5 percent of patients with type 2 diabetes and

Yahoo Creators — Feeling awful on your GLP-1? The drug may not be what's making you miserable - Y

Feeling awful on your GLP-1? The drug may not be what's making you miserable - Yahoo Creators Source: Yahoo Creators Published: Sun, 11 Oct 2026 20:24:43 GMT Most people who start taking a GLP-1 medication aren't taking it a year later. The gap between the expectations and reality is startling for many patients, and the numbers might surprise you. For instance, a cohort study of more than 125,000 adults published in JAMA Network Open found that 46.5 percent of patients with type 2 diabetes and

Yahoo Creators — Feeling awful on your GLP-1? The drug may not be what's making you miserable - Y

Feeling awful on your GLP-1? The drug may not be what's making you miserable - Yahoo Creators Source: Yahoo Creators Published: Sun, 11 Oct 2026 20:24:43 GMT Most people who start taking a GLP-1 medication aren't taking it a year later. The gap between the expectations and reality is startling for many patients, and the numbers might surprise you. For instance, a cohort study of more than 125,000 adults published in JAMA Network Open found that 46.5 percent of patients with type 2 diabetes and

Yahoo Creators — Feeling awful on your GLP-1? The drug may not be what's making you miserable - Y

Feeling awful on your GLP-1? The drug may not be what's making you miserable - Yahoo Creators Source: Yahoo Creators Published: Sun, 11 Oct 2026 20:24:43 GMT Most people who start taking a GLP-1 medication aren't taking it a year later. The gap between the expectations and reality is startling for many patients, and the numbers might surprise you. For instance, a cohort study of more than 125,000 adults published in JAMA Network Open found that 46.5 percent of patients with type 2 diabetes and

Yahoo Creators — Feeling awful on your GLP-1? The drug may not be what's making you miserable - Y

Feeling awful on your GLP-1? The drug may not be what's making you miserable - Yahoo Creators Source: Yahoo Creators Published: Sun, 11 Oct 2026 20:24:43 GMT Most people who start taking a GLP-1 medication aren't taking it a year later. The gap between the expectations and reality is startling for many patients, and the numbers might surprise you. For instance, a cohort study of more than 125,000 adults published in JAMA Network Open found that 46.5 percent of patients with type 2 diabetes and

PubMed — Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

1. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Thomsen RW(1), Mailhac A(1), Løhde JB(2)(3), Pottegård A(4). Author information: (1)Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. (2)Department of Biomedicine, Aarhus University, Aarhus, De

ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide… — Nausea

Posted trial results for A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (NCT04596631, PHASE3). In the "Placebo" arm (n=66 at risk), Nausea occurred in 9 participants (13.6%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Baseline (Week 0) up to 57 weeks

ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide… — Dizziness

Posted trial results for A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (NCT04596631, PHASE3). In the "Placebo" arm (n=66 at risk), Dizziness occurred in 2 participants (3.0%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Baseline (Week 0) up to 57 weeks

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Vomiting

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A Placebo" arm (n=8 at risk), Vomiting occurred in 0 participants (0.0%). Conditions: Healthy. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Follow-up (up to Day 42)

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Decreased appetite

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (NCT02906930, PHASE3). In the "Placebo" arm (n=178 at risk), Decreased appetite occurred in 1 participants (0.6%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 31 (26 weeks treatment period + 5 weeks follow-up p

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Vomiting

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Vomiting occurred in 3 participants (2.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are bas

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Nausea

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Nausea occurred in 5 participants (3.5%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are based

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Headache

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Headache occurred in 8 participants (5.6%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are bas

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Diarrhoea

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Diarrhoea occurred in 11 participants (7.7%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are b

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Decreased appetite

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Decreased appetite occurred in 0 participants (0.0%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Resul

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Constipation

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Constipation occurred in 4 participants (2.8%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Liraglutide… — Abdominal pain

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (NCT02863419, PHASE3). In the "Placebo" arm (n=142 at risk), Abdominal pain occurred in 3 participants (2.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results a

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Dizziness

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557, PHASE3). In the "Placebo" arm (n=367 at risk), Dizziness occurred in 18 participants (4.9%). Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF). Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up To 162 Weeks

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557, PHASE3). In the "Placebo" arm (n=367 at risk), Decreased appetite occurred in 6 participants (1.6%). Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF). Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up To 162 Weeks

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Nausea

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557, PHASE3). In the "Placebo" arm (n=367 at risk), Nausea occurred in 23 participants (6.3%). Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF). Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up To 162 Weeks

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Diarrhoea

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (NCT04847557, PHASE3). In the "Placebo" arm (n=367 at risk), Diarrhoea occurred in 23 participants (6.3%). Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF). Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up To 162 Weeks

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Vomiting

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (NCT03021187, PHASE3). In the "Placebo" arm (n=184 at risk), Vomiting occurred in 7 participants (3.8%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are based

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Nausea

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (NCT03021187, PHASE3). In the "Placebo" arm (n=184 at risk), Nausea occurred in 13 participants (7.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are based

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Diarrhoea

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (NCT03021187, PHASE3). In the "Placebo" arm (n=184 at risk), Diarrhoea occurred in 11 participants (6.0%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results are bas

ClinicalTrials.gov results — Efficacy and Safety of Oral Semaglutide Versus Placebo in… — Decreased appetite

Posted trial results for Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (NCT03021187, PHASE3). In the "Placebo" arm (n=184 at risk), Decreased appetite occurred in 2 participants (1.1%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Week 0 to week 57 (52 weeks treatment period + 5 weeks follow-up period). Results

ClinicalTrials.gov results — A Research Study to Compare a Medicine Called Semaglutide… — Nausea

Posted trial results for A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (NCT04560998, PHASE3). In the "Placebo" arm (n=395 at risk), Nausea occurred in 3 participants (0.8%). Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Until week 57

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Vomiting

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830, PHASE3). In the "Placebo" arm (n=285 at risk), Vomiting occurred in 15 participants (5.3%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up t

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Constipation

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830, PHASE3). In the "Placebo" arm (n=285 at risk), Constipation occurred in 11 participants (3.9%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for

ClinicalTrials.gov results — GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2… — Dizziness

Posted trial results for GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (NCT00713830, PHASE3). In the "Placebo" arm (n=285 at risk), Dizziness occurred in 18 participants (6.3%). Conditions: Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: First dose of study drug up to 3 days after the last dose administration, for up

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Decreased appetite

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Decreased appetite occurred in 6 participants (1.7%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Fatigue

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Fatigue occurred in 16 participants (4.6%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Vomiting

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Vomiting occurred in 21 participants (6.0%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Nausea

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Nausea occurred in 42 participants (12.1%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Diarrhoea

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Diarrhoea occurred in 38 participants (10.9%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — The Efficacy and Safety of Liraglutide as Adjunct Therapy… — Constipation

Posted trial results for The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523, PHASE3). In the "Placebo" arm (n=348 at risk), Constipation occurred in 9 participants (2.6%). Conditions: Diabetes, Diabetes Mellitus, Type 1. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Up to 52 weeks

ClinicalTrials.gov results — Evaluation of Cardiovascular Outcomes in Patients With Type… — Diarrhoea

Posted trial results for Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (NCT01147250, PHASE3). In the "Placebo" arm (n=3032 at risk), Diarrhoea occurred in 227 participants (7.5%). Conditions: Acute Coronary Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: All Adverse Events (AEs) were collected from signature of the informed

ClinicalTrials.gov results — Evaluation of Cardiovascular Outcomes in Patients With Type… — Nausea

Posted trial results for Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (NCT01147250, PHASE3). In the "Placebo" arm (n=3032 at risk), Nausea occurred in 179 participants (5.9%). Conditions: Acute Coronary Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: All Adverse Events (AEs) were collected from signature of the informed con

ClinicalTrials.gov results — Evaluation of Cardiovascular Outcomes in Patients With Type… — Headache

Posted trial results for Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (NCT01147250, PHASE3). In the "Placebo" arm (n=3032 at risk), Headache occurred in 148 participants (4.9%). Conditions: Acute Coronary Syndrome. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: All Adverse Events (AEs) were collected from signature of the informed c

ClinicalTrials.gov results — Liraglutide Effect and Action in Diabetes: Evaluation of… — Nausea

Posted trial results for Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (NCT01179048, PHASE3). In the "Placebo" arm (n=4672 at risk), Nausea occurred in 129 participants (2.8%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse events from randomisation (visit 3; month 0) and until follow up (visit 16; up to month 60+30 days of post-treat

ClinicalTrials.gov results — Liraglutide Effect and Action in Diabetes: Evaluation of… — Diarrhoea

Posted trial results for Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (NCT01179048, PHASE3). In the "Placebo" arm (n=4672 at risk), Diarrhoea occurred in 102 participants (2.2%). Conditions: Diabetes, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Adverse events from randomisation (visit 3; month 0) and until follow up (visit 16; up to month 60+30 days of post-tr

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Headache

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Headache occurred in 288 participants (5.8%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Dizziness

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Dizziness occurred in 296 participants (6.0%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Decreased appetite

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Decreased appetite occurred in 104 participants (2.1%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Nausea

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Nausea occurred in 269 participants (5.4%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Diarrhoea

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Diarrhoea occurred in 436 participants (8.8%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — Researching Cardiovascular Events With a Weekly Incretin in… — Constipation

Posted trial results for Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952, PHASE3). In the "Placebo" arm (n=4949 at risk), Constipation occurred in 208 participants (4.2%). Conditions: Cardiovascular Disease, Diabetes Mellitus, Type 2. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: From Randomization to Study Completion (Up to 7 Years)

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Dizziness

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Dizziness occurred in 5 participants (1.6%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Nausea

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Nausea occurred in 20 participants (6.3%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Diarrhoea

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Diarrhoea occurred in 28 participants (8.9%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With… — Abdominal pain

Posted trial results for A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (NCT04657003, PHASE3). In the "Placebo" arm (n=315 at risk), Abdominal pain occurred in 7 participants (2.2%). Conditions: Type 2 Diabetes, Overweight, Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline through Week 76

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Alopecia

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Alopecia occurred in 23 participants (2.4%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Fatigue

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Fatigue occurred in 15 participants (1.6%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Vomiting

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Vomiting occurred in 33 participants (3.5%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74

ClinicalTrials.gov results — A Study of Orforglipron (LY3502970) in Adult Participants… — Gastrooesophageal reflux disease

Posted trial results for A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903, PHASE3). In the "Placebo" arm (n=948 at risk), Gastrooesophageal reflux disease occurred in 21 participants (2.2%). Conditions: Obesity, Overweight, Overweight or Obesity. Source: ClinicalTrials.gov results section, adverse events module. AE listing threshold: 5. AE counting window: Baseline Up to Week 74